Related Experiment Video
Updated: May 31, 2026
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Erlotinib in glioblastoma: lost in translation?
Georg Karpel-Massler1, M Andrew Westhoff, Richard E Kast
1Department of Neurosurgery, University of Ulm, Ulm, Germany.
Abstract:
Glioblastoma represents the most common primary brain tumor in adults. Despite improvements of multimodal therapy, the prognosis of this disease remains unfavorable. Thus, great efforts have been made to identify therapeutic agents directed against those specific molecular targets whose presence was shown to be associated with worse clinical outcomes. The epidermal growth factor receptor (HER1/EGFR) has been identified as one such target, and different compounds were developed to inhibit HER1/EGFR and/ or its mutant form, EGFRvIII. However, clinical trials did not confirm the initial enthusiasm conveyed by promising results from experimental studies. Therefore, a therapeutic approach directed at inhibiting solely HER1/EGFR does not seem to translate into a clinical benefit. This review discusses the current therapeutic situation in the setting of glioblastoma while putting the spotlight on erlotinib, a HER1/EGFR-targeted small molecule tyrosine kinase inhibitor.
Insights
Glioblastoma treatment faces challenges despite advances. Targeting the epidermal growth factor receptor (EGFR) alone, like with erlotinib, has not improved patient outcomes, necessitating new therapeutic strategies.
Area of Science:
- Neuro-oncology
- Molecular targeted therapy
- Cancer research
Background:
- Glioblastoma is the most common adult primary brain tumor with a poor prognosis.
- Multimodal therapy has shown limited success in improving patient outcomes.
- Epidermal growth factor receptor (EGFR) and its mutant form (EGFRvIII) are key molecular targets in glioblastoma.
Purpose of the Study:
- To review the current therapeutic landscape for glioblastoma.
- To evaluate the efficacy of targeting HER1/EGFR in glioblastoma treatment.
- To discuss the role of erlotinib as a HER1/EGFR inhibitor.
Main Methods:
- Review of existing literature on glioblastoma therapies.
- Analysis of clinical trial data for EGFR-targeted agents.
- Discussion of preclinical and clinical findings related to erlotinib.
Main Results:
- Despite promising preclinical data, clinical trials targeting HER1/EGFR have not yielded significant clinical benefit.
- Solely inhibiting HER1/EGFR has not translated into improved survival rates for glioblastoma patients.
- Erlotinib, a HER1/EGFR inhibitor, has shown limited efficacy in clinical settings.
Conclusions:
- Targeting HER1/EGFR alone is insufficient for effective glioblastoma treatment.
- The clinical benefit of HER1/EGFR inhibition in glioblastoma remains unproven.
- Further research is needed to identify more effective therapeutic strategies for glioblastoma.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014